Protagonist Therapeutics' Second Quarter 2025 Financial Results

Protagonist Therapeutics has released its financial results for the second quarter of 2025, highlighting significant milestones and financial standing. A New Drug Application (NDA) for icotrokinra, targeting moderate to severe plaque psoriasis, was submitted in July to the U.S. FDA. Additionally, Phase 3 trial data of rusfertide for polycythemia vera was presented and a U.S. NDA filing is anticipated in Q4.

Financially, Protagonist reported cash and equivalents of $673 million as of June 30, expected to sustain the company until the end of 2028. However, the second quarter saw a net loss of $34.8 million, compared to $30.6 million in the same quarter of the previous year. The company continues to focus on developing its early-stage assets and advancing its clinical programs.